Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$21.93
+$0.05 · +0.23%
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Previous close
$21.93
+$0.05 · +0.23%
Pre-market
$21.66
−$0.27 · -1.23%
Oct 8, 4:52 AM ET
Regular session · ET · Market data may be delayed.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Day range
Current $21.93
52-week range
Current $21.93
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
98
Deep Value
Sentiment
60
Mixed
Risk
44
Elevated Risk
Momentum
40
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Day range
Current $21.93
52-week range
Current $21.93
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 780.57M USD | 631.45M USD | 566.77M USD | 463.93M USD | 276.87M USD |
| Cost of goods sold | 317.31M USD | 254.11M USD | 240.6M USD | 254.45M USD | 126.25M USD |
| Gross profit | 463.26M USD | 377.34M USD | 326.17M USD | 209.49M USD | 150.62M USD |
| Research and development | — | — | — | 3.98M USD | 9.45M USD |
| Selling, general, and administrative | 276.17M USD | 182.98M USD | 159.21M USD | 172.19M USD | 118.96M USD |
| Operating expenses | 276.17M USD | 207.45M USD | 159.21M USD | 176.17M USD | 132.99M USD |
| Interest income | 11.29M USD | 13.98M USD | 15.62M USD | 1.05M USD | 12K USD |
| Interest expense | 82.31M USD | 73.97M USD | 83.34M USD | 63.21M USD | 21.01M USD |
| Depreciation and amortization | 226.07M USD | 169.16M USD | 149.26M USD | 138.94M USD | 68.92M USD |
| Operating income | 187.08M USD | 169.9M USD | 166.96M USD | 33.32M USD | 17.63M USD |
| Net income | 62.87M USD | 69.19M USD | 48.16M USD | −25M USD | 71.52M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$48.00
118.88% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI24.07M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM18.72M0.02%78.56B USD0.19%$277.7-1.29%
Invesco Pharmaceuticals ETFPJP14.15M2.61%542.27M USD0.58%$121.53+0.68%
Avantis U.S. Small Cap Value ETFAVUV10.4M0.03%30.86B USD0.25%$119.13-1.11%
Invesco Biotechnology & Genome ETFPBE9.33M2.26%412.1M USD0.59%$94.66-0.04%
Vanguard Extended Market ETFVXF9.25M0.01%95.4B USD0.05%$233.49-1.56%
State Street SPDR S&P Pharmaceuticals ETFXPH9.17M1.88%462.1M USD0.35%$62.910.00%
Pacer US Small Cap Cash Cows ETFCALF6.75M0.19%3.56B USD0.59%$53.83-0.73%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMInvesco Pharmaceuticals ETFPJPAvantis U.S. Small Cap Value ETFAVUVInvesco Biotechnology & Genome ETFPBEVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHPacer US Small Cap Cash Cows ETFCALFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
